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Abstract
Pneumococcal conjugated vaccines have been recommended in children for over a decade in many countries worldwide. Here we
review the development of pneumococcal vaccines with a focus on the two types currently available for children and their safety
record. We discuss also the effect of vaccines, including the 13-valent pneumococcal conjugate vaccine, on invasive pneumococcal dis-
eases in children, particularly bacteraemia, pneumonia and meningitis, as well as on mucosal disease and carriage. In regions where
immunization was implemented in young children, the number of invasive pneumococcal diseases decreased significantly, not only in the
target age group, but also in younger and much older subjects. Challenges and future perspectives regarding the development of new
‘universal’ vaccines, which could bypass the current problem of serotype-specific protection in a context of serotype replacement, are
also discussed.
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Introduction
Diseases caused by Streptococcus pneumoniae (pneumococcus)
constitute a major global public health problem. According
to the WHO, about 14.5 million episodes of serious pneu-
mococcal disease (uncertainty range 11.1–18.0 million) were
estimated to have occurred in 2000, resulting in about
826 000 deaths (uncertainty range: 582 000–926 000) in chil-
dren aged 1–59 months [1].
Pneumococcus-related diseases are considered as the
number one vaccine-preventable cause of death in children
[2]. Pneumococcus causes mucosal diseases, such as acute
otitis media, sinusitis, mastoiditis and other serious diseases,
called invasive pneumococcal diseases (IPD), which include
bacteraemia, meningitis, or pneumonia. The overall rate of
IPD among children and adults is reported to be about 15/
100 000 individuals per year [2]. Certain ethnic groups, such
as African-Americans, Native Americans and Australian
Aboriginals, are up to ten times more at risk for invasive
disease, although it remains unclear whether this is the result
of genetic components or environmental factors [3–5]. The
main objective of pneumococcal vaccination in children is to
decrease the incidence of IPD, but also to help prevent
mucosal disease.
Almost all S. pneumoniae have an external polysaccharide
capsule and more than 90 serotypes have been identified on
the basis of antigenic differences in this capsule [6–8]. Strep-
tococcus pneumoniae usually colonizes the nasopharynx and
repeated sampling can yield a positive culture in up to 70%
of patients, especially in children [9]. In general, infants are
first colonized by 6 months of age and remain positive for
approximately 4 months [10,11]. Many factors influence the
risk of developing disease and are more likely to promote
the spread of pneumococcus than only episodic contact, such
as contact time, repeated exposure, the quantity of transmit-
ted bacteria, or crowded living conditions [12]. Host clear-
ance mechanisms can be either mechanical, such as ciliary
action, or immunological [6]. In the presence of coexisting
infection (usually viral) or chronic ciliary damage (e.g. in
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smokers), these clearance mechanisms may be impaired and
favour pneumococcal extension and replication.
Pneumococcal vaccines
The first pneumococcal vaccine trial started in 1911 with a
killed whole-cell vaccine and was conducted among South
African miners with a particularly high incidence of lobar
pneumonia [13]. Thirty years later, a purified capsular poly-
saccharide vaccine was tested in military recruits in the USA
[14]. Following encouraging results, two hexavalent polysac-
charide vaccines became available in the USA in 1946. How-
ever, as the newly available antimicrobials had a ‘miraculous’
efficacy against lobar pneumonia, interest for these vaccines
waned quickly, leading to their withdrawal from the market
in 1954 [13,15]. Pneumococcal vaccines became again a sub-
ject of interest in the 1970s because of the emergence of
pneumococcal strains with a reduced susceptibility to antimi-
crobials.
Two different types of pneumococcal vaccines are
currently available: a polysaccharide vaccine and conjugated
vaccines (Table 1). The unconjugated pneumococcal polysac-
charide vaccine (Pneumovax23, Merck, Whitehouse Station,
NJ, USA) is non-adjuvanted and contains purified capsular
polysaccharides from 23 different serotypes (Table 2). Pneu-
mococcal polysaccharide vaccine induces a B-cell response
with the production of anticapsular opsonizing immunoglobu-
lin, but no T-cell response. It is usually recommended for all
adults over 65 years of age and for children older than
2 years with a high-risk medical condition, e.g. immunosup-
pression, asplenia (functional or anatomic), chronic diseases
(including chronic heart, lung and liver diseases, diabetes
mellitus, cerebrospinal fluid leaks and cochlear implant), alco-
hol abuse and tobacco use [16,17]. Although the US Advi-
sory Committee on Immunization Practices does not
recommend routine re-vaccination with PPSV, some coun-
tries recommend a second dose after 5 years if the first
dose was given before the age of 65 years, and in individuals
<65 years old with certain high-risk conditions, such as
immunosuppression and anatomical or functional asplenia
[16–18].
Pneumococcal polysaccharide vaccine is usually not immu-
nogenic in children <2 years old. To protect younger chil-
dren, pneumococcal conjugated vaccines (PCV) were
developed. Prevenar 7 (or Prevnar 7; Pfizer Inc. [formerly
Wyeth], New York, NY, USA) was licensed in 2000. It con-
tains polysaccharides from seven serotypes (Table 2) conju-
gated to a protein carrier CRM197, a non-toxic mutant of
the diphtheria toxin, with an alum-bound adjuvant, and has
the capacity to induce both T-cell and B-cell responses. Since
2010, PCV13 (Prevenar13; Pfizer Inc. (formerly Wyeth))
has replaced PCV7 and includes new serotypes in addition to
the previous serotypes (Table 2). Recent studies showed that
PCV13 is as immunogenic as PCV7 for both the common
serotypes and additional serotypes [17,19–21]. In a non-infe-
riority study comparing infants with pneumococcal IgG levels
‡0.35 mg/L, the percentage reached for PCV13 vs. PCV7
was the following for each serotype: 4: 94.4% vs. 98% (95%
CI for the difference in proportions: )7.3 to 0.1); 6B: 87.3%
vs. 92.8% ()10.9 to )0.1); 9V: 90.5% vs. 98.4% ()12.4 to
)4.0); 14: 97.6% vs. 97.2% ()2.7–3.5); 18C: 96.8% vs. 98.4%
()4.7–1.2); 19F: 98% vs. 97.6% ()2.4–3.4); 23F: 90.5% vs.
94% ()8.5–1.2); and for the serotypes only included in
PCV13: 1: 95.6%; 3: 63.5%; 5: 89.7%; 6A: 96%; 7F: 98.4%;
19A: 98.4% [17]. The safety profile is also comparable. Syn-
florix (GlaxoSmithKline, London, UK) is a ten-valent PCV
also used in Europe. Based on the ELISA threshold, non-infe-
riority of this PCV10 compared with PCV7 was demon-
strated for eight out of ten serotypes (it was not reached
for 6B and 23F), although post-hoc analysis of the percentage
of children with opsonophagocytic titres ‡8 suggested non-
inferiority for the seven serotypes common to both vaccines
[22]. Several studies have also shown that PCV10 could be
co-administered with other childhood vaccines [23–27], and
that it could also induce immunological memory [28]. Since
TABLE 1. Name, producer, and date of general availability of different pneumococcal vaccines (polysaccharide and conjugate)
Vaccines
PPSV23 Pneumovax23, Merck, Whitehouse Station, NJ, USA
Pnu-Immune23, Lederle Laboratories, Pearl River, NY, USA
Available since 1983
Available since 1979
PCV7 Prevenar 7, Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA (part of Pfizer, New York, NY, USA) Available since 2000
PCV9 Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA (part of Pfizer, New York, NY, USA) Clinical studies in 2000–2005
PCV10 Synflorix, GlaxoSmithKline, London, UK Available since 2009
PCV11 Sanofi Pasteur, Lyon, France Clinical studies in 2001–2004 (Europe)
PCV13 Prevenar13, Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA (part of Pfizer, New York, NY, USA) Available since 2010
PCV15 Department of Vaccines Research, Merck & Co., Whitehouse Station, NJ, USA Preclinical studies (state in 2011)
PPSV, pneumococcal polysaccharide vaccine; PCV, pneumococcal conjugate vaccine.
The numbers following the vaccine reflect the valence.
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2007, WHO recommends that all countries incorporate
PCV into their national infant immunization programmes
(Table 3) [29]. Simultaneous administration with other vac-
cines is possible, provided that the injection is administered
with a separate syringe at a separate site [17]. National
guidelines usually recommend two to three doses during the
first year of life and a booster dose in the second year of life
(Table 3).
Knuf et al. [30] demonstrated that the appropriate anti-
body response was achieved after the third dose of PCV7 in
>98% (95% CI 95.84–100.66 for serotypes 9V and 23F; 95%
CI 100–100 for the others) of subjects. Other authors con-
firmed these results and reported that the so-called ‘protec-
tive’ level (>0.35 mg/L) was reached in >82% of subjects
after three doses, independent of the chosen immunization
schedule (at 2, 4 and 6 months, or 2, 3 and 4 months)
[31,32]. WHO now recommends that approval of new pneu-
mococcal vaccines should be based on non-inferiority data
compared with PCV7, which should include the proof of
development of protective and functional antibodies in vacci-
nated subjects after a primary series and a test of immune
memory [33]. This was demonstrated for PCV13 where
immunogenicity studies showed that it was not only similarly
immunogenic against the PCV7-containing serotypes, but also
against the new serotypes [17,34,35]. Any evaluation of the
value of pneumococcal vaccination in children must take into
account not only the immunogenicity data, but also the epi-
demiological and safety data.
Invasive pneumococcal disease
The overall estimated protection against IPD was reported
in the pre-licensure study by Black et al. [36] in 2000 where
52 cases of IPD caused by vaccine serotypes (19F, 19F and
6B) were reported after immunizing > 38 000 young children
in the intent-to-treat analysis [12]. The three vaccine failures
included a fully vaccinated child, one child who developed
acute myelogenous leukaemia after vaccination and became
bacteraemic while receiving chemotherapy, and one child who
had received a single dose of PCV7 almost a year earlier.
In the intention-to-treat analysis, the efficacy of PCV7 was
shown to be 93.9% (95% CI 79.6–98.5, p 0.001) with a
reduction in the total IPD burden of 89% (95% CI 73.7–
95.85, p <0.001) following at least one dose [30]. Other lab-
oratory-based and surveillance-based studies showed similar
results, particularly in children <5 years old. In 1998–99,
Whitney et al. [37] estimated the overall IPD rate in the
USA at 24.3 cases per 100 000 and in 2001 at 17.3/100 000.
This significant decrease was particularly important among
children <2 years old, in whom the disease rate decreased
by 69% (95% CI 62–75, p <0.001) [37]. Since then, these
results have been confirmed in several studies [38–40]. The
Active Bacterial Core surveillance, a core component of the
US CDC Emerging Infections Programs network, showed a
decrease of IPD of 76% (95% CI 73–79; 98.7 to 23.6/
100 000 for all serotypes) in children <5 years old, and the
serotypes included in PCV7 showed a decrease of 99.5%
(95% CI 99–100; from 81.9 to 0.4/100 000) [41]. This was
less spectacular in older children (5–17 years old), but
remained significant (43% decrease, 95% CI 26–55 for all ser-
otypes combined; form 5.17 to 4.2/100 000). Williams et al.
[42] showed a decrease of 74% (p <0.001) in all children
<2 years old in Australia. This reduction in the younger age
group was less significant in Germany, where Ru¨ckinger et al.
[43] reported a decrease of 45% of IPD (from 20, 95% CI
19.1–20.9 to 11, 95% CI 9.3–12.9/100 000 cases), which may
be a result of the lower vaccination coverage (Table 3).
Herd immunity
Interestingly, the vaccination of young children had an indi-
rect effect on very young infants, i.e. those too young to be
vaccinated. Givon-Lavi et al. [44] demonstrated this in Israel
in a randomized double-blind study in which 262 children
were followed for 2 years after receiving either PCV9 or a
control vaccine. As expected, vaccine-serotype carriage
decreased in PCV9 recipients, but a parallel reduction among
their younger, unvaccinated siblings was also observed.
Furthermore, when acquired, vaccine-serotype, drug-resis-
tant S. pneumoniae was cleared faster in siblings of PCV9
TABLE 2. Serotype composition of currently available pneumococcal vaccines (polysaccharide and conjugated)
Vaccines Pneumococcal serotypes included
PPSV23 1 2 3 4 5 6A 6B 7F 8 9N 9V 10A 11A 12F 14 15B 17F 18C 19A 19F 20 22F 23F 33F
PCV7 4 6B 9V 14 18C 19F 23F
PCV9 1 4 5 6B 9V 14 18C 19F 23F
PCV10 1 4 5 6B 7F 9V 14 18C 19F 23F
PCV11 1 3 4 5 6B 7F 9V 14 18C 19F 23F
PCV13 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F
PCV15 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 22F 23F 33F
PPSV, pneumococcal polysaccharide vaccine; PCV, pneumococcal conjugate vaccine.
The numbers following the vaccine reflect the valence.
CMI Pittet and Posfay-Barbe Pneumococcal vaccines for children 27
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 25–36
TABLE 3. Pneumococcal vaccine schedules and coverage in European countries and other selected WHO regions
Country Vaccine
Schedule
Comments
% target population
vaccinated in 2010*Primary doses Booster dose
Europe 12
Albania PCV 2, 4, 6 months From 03/2011 NA
Andorra PCV 3, 5 months 15 months NS
Austria PCV 3 doses (within 1st
year of life)
1–2 years HRG NS
Belgium PCV 8, 16 weeks 12 months HRG < 2 years 84
Bulgaria PCV 2, 3, 4months 12 months 69
Cyprus PCV 2, 4, 6 months 12–15 months NS
Czech Republic PCV 4, 5, 6 months 11–18 months NS
Denmark PCV 3, 5 months 12 months 88
Finland PCV 3, 5 months 12 months HRG > 2 years NS
PPSV <5 years Certain diseases
France PCV 2, 4 months 12 months NS
Germany PCV 2, 3, 4 months 11–14 months 9
PPSV >60 years
Greece PCV 2, 4, 6 months 12–18 months NS
PPSV ‡60 years & HRG 2–60 years
Hungary PCV 2, 4 months 15 months NS
(first dose: 89%)
Iceland PPSV ‡60 years NS
Ireland PCV 2, 6 months 12 months 88
PPSV ‡2 years At risk
Israel PCV 2, 4 months 12 months NS
PPSV ‡65 years Risk groups
Italy PCV 3, 5 months 11–12 months Children with
clinical indications
NS
PPSV HRG
Kazakhstan PCV 2, 4 months 12 months From 2011 NA
Latvia PCV 2, 4, 6 months NS (first dose: 64%)
Lithuania PCV 2, 3, 4 months 12–14 months From 9/2011 NA
Luxembourg PCV 2, 3, 4 months 12 months 86
PPSV ‡60 years
Malta PCV 2, 4 months 12 months From 2011 NS
Monaco PPSV 2 months NS
The Netherlands PCV 2, 3, 4 months 11 months 96
Norway PCV 3, 5 months 12 months 91
Republic of Moldovia PCV From 1/2013 NA
Serbia PPSV HRG NS
Slovakia PCV 2, 4 months 10 months 99
Slovenia PCV NS NS HRG NS
PPSV HRG
Spain PCV 2, 4, 6 months 15–18 months HRG NS
PPSV >65 years HRG
Sweden PCV 3, 5 months 12 months NS
PPSV >65 years
Part of country
HRG
Switzerland PCV 2, 4 months 12 months NS
PPSV >65 years
Turkey PCV 2, 4, 6 months 12 months NS
UK and Northern Ireland PCV 2, 4 months 12 months 95
PPSV ‡65 years HRG > 2 years
Africa PCV 4
Benin PCV 6, 10, 14 weeks NS
Cameroon PCV From 7/2011 NA
Central African Republic PCV 6, 10, 14 weeks From 7/2011 NA
Democratic Republic
of the Congo
PCV 6, 10, 14 weeks From 4/2011 NA
Gambia PCV 2, 3, 4 months 99
Madagascar PCV From 10/2011 NA
Rwanda PCV 6, 10, 14 weeks 80
South Africa PCV 6, 14 weeks 9 months 64
Americas PCV 28
Brazil PCV 2, 4, 6 months 15 months 24
PPSV >2, 7 and >60 years HRG NS
Canada PCV 2, 4, 6 months 12–15 months NS
Costa Rica PCV 2, 4, 6 months 15 months 94
PPSV HRG NS
USA PCV 2, 4, 6 months 12–15 months & HRG>15 months NS
PPSV >2 years HRG NS
Mexico PCV 2, 4 months 12 months 92
PPSV 65 years NS
Eastern Mediterranean PCV 5
South-East Asia NS
Western Pacific PCV 1
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recipients than in siblings of controls (p 0.03). A multicentre
study analysing 146 IPD, mostly bacteraemia, in infants
<90 days old showed a 40% decrease (from 11.8 to 7.2/
100 000 live births; p 0.004) decrease after PCV7 was
introduced in the population [45]. Similarly, while the hospi-
talization rate for IPD decreased in another study by 80%
(95% CI 76–84) in the 0–1-year-old group (27.8–5.5/
100 000 cases), the reduction was also significant in older
children (65%, 95% CI 53–73, in 2–4 year olds; 53%, 95%
CI 40–64, in 5–17 year olds), hence reflecting herd immu-
nity [46]. Since the introduction of PCV, several studies
have shown a decrease in the incidence of invasive pneu-
mococcal disease not only in older children but also in
adults, as well as a reduction of drug-resistant pneumococ-
cal disease and carriage [41,47–52]. Haber et al. [53] calcu-
lated, using a quantitative model to estimate the herd
effects on the incidence of invasive disease, that vaccinating
young children with at least one dose significantly
decreased invasive disease due to vaccine-serotypes in all
age groups >5 years of age. O’Brien and Dagan [54] also
summarized the early results regarding the impact of PCV
on nasopharyngeal carriage of non-vaccine serotypes, which
increased in several studies [55].
Since the introduction of PCV7, serotypes not included in
the vaccine have become much more prevalent. This phe-
nomenon, known as serotype replacement, has probably
occurred as the result of a combination of factors and is well
summarized by Henriques-Normark et al. [56]. The most
common new serotypes reported in IPD are 1, 19A, 3, 6A
and 7F [57]. The greatest increase in children <5 years old
was observed with 19A, but other serotypes such as 11, 15,
33 and 35 have also emerged in the last decade [38,41,58–
62]. The emergence of 19A can be linked to several factors.
It has been observed that countries with high rates of sero-
type 19A IPD or nasopharyngeal carriage also had high rates
of antibiotic use, suggesting that antibiotic pressure played a
role in the emergence of this serotype [63–66]. In addition,
authors have suggested that vaccine-induced serotype
replacement, introduction of new clones, or secular trends
explain the increase of serotype 19A. Reinert et al. [67] sum-
marize the prevalence of serotype 19A in different settings.
Although it became rapidly clear that serotype 19A would
take the lead in industrialized countries as an important
player in IPD, it was probably less expected that the propor-
tion of antibiotic-resistant 19A would increase as fast in both
PCV7-vaccinated and PCV7-non-vaccinated individuals [68–
73]. Manufacturers introduced PCV13 in 2010, a broader
version of PCV7, which contained most of these emerging
serotypes, and included serotypes—such as 1 and 5—which
are more prevalent in developing countries as a cause of
IPD—or such as serotypes 1 and 3 in pulmonary empyema
[74,75]. The results of the first surveillance data are only
now being reported, but the observed and expected impact
of PCV13 is clearly beneficial [76–81]. In Alaskan Native chil-
dren, a high-risk population, the incidence of IPD has
decreased dramatically since the start of PCV13 vaccination
and no new IPD cases were observed after these children
received at least one dose of PCV13 [82]. Similarly, Active
Bacterial Core surveillance data showed a decrease in IPD in
vaccinated children <2 years old soon after implementation
of PCV13 (in the fourth quarters of 2006–2008 compared
with 2010: overall serotypes: 40.3–18.8/100 000 cases;
PCV13 serotypes: 24.1–8.5/100 000 cases, both
p <0.0001)[83].
TABLE 3. (Continued)
Country Vaccine
Schedule
Comments
% target population
vaccinated in 2010*Primary doses Booster dose
Australia PCV 2, 4, 6 months 18–24 months
(PCV10 only)
PCV7 or PCV10. The dose at
18–24 months is only given
with the 10-valent vaccine
91
PPSV 18–24 months
15–49 years
‡50 years
‡65 years
Part of country
Aboriginal and Torres Strait
Islander people
NA
New Zealand PCV 6 weeks; 3, 5
months
15 months 89
PPSV HRG NS
Singapore PCV 3, 5 months 1–2 years NS
PPSV HRG NS
Global world estimated coverage 6
Adapted from the references [114,115].
*Percent of target population vaccinated in 2010 expresses the percentage of individuals fully immunized with PCV among those targeted by the country’s PCV immunization
recommendations.
PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine; NS, not specified; NA, not applicable; HRG, high-risk group.
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Bacteraemia
Bacteraemia data are often included in the overall IPD
results. However, a retrospective study of data from 1106
positive blood cultures in previously healthy children
<3 years old in the USA showed a decrease in the propor-
tion of pneumococcal bacteraemia from 78% in 1998–99 to
26% in 2001–02, with a decrease in the total number of posi-
tive blood cultures [84]. Similarly, in Spain, the total number
of occult pneumococcal bacteraemia decreased by 57.5%
(p <0.05) after the implementation of PCV7, and the rate
attributed to PCV7 serotypes decreased significantly by 79%
(p <0.01) [85]. In France, vaccine-type bacteraemia decreased
by 64% from 14.8 to 5.3/100 000 children between 2001/02
and 2006, although PCV7 coverage in 6–12-month-old chil-
dren was only 44% in 2006 [86]. According to epidemiologi-
cal data, PCV13 should have an even more pronounced
effect on bacteraemia [87,88].
Pneumonia
A reanalysis of all pneumonia cases of the PCV7 pre-licen-
sure US study using the WHO standardized methodology
for the classification of clinical pneumonia showed a per-pro-
tocol analysis effectiveness of 30.3% (95% CI 10.7–45.7;
intent-to-treat analysis 25.5%; 95% CI 6.5–40.7) for the pre-
vention of pneumonia [89]. In a randomized, double-blind,
placebo-controlled trial with a nine-valent conjugate vaccine
conducted in the Gambia in >17 000 children aged 6–
51 weeks, the efficacy of PCV to prevent against a first epi-
sode of pneumonia was 37% (95% CI 27–45), with a 16%
(95% CI 3–28) efficacy against mortality [90]. However,
there was no significant efficacy in the severity of disease.
Another US study of surveillance data found that non-bacte-
raemic pneumococcal pneumonia decreased by 47% in chil-
dren <2 years old after PCV7 was introduced [46]. This was
observed particularly in those <12 months old, in whom all-
cause pneumonia decreased from 1026.5 to 753.7/100 000
admissions in the post-PCV7 era. Of note, the effect of
pneumococcal vaccination was not apparent for annual
admission rates for pneumonia with empyema in young chil-
dren [91]. This could be due to the fact that empyema is
more frequent with certain serotypes that are not included
in PCV7—such as 19A, 3 and 1—but that are now included
in PCV13 [92]. This was confirmed by Spencer et al. [93]
who recently reported a decrease in the incidence of empy-
ema in children vaccinated with PCV13 (regression coeffi-
cient )0.26).
Meningitis
In a US surveillance study of children <5 years old, the
reported decrease in vaccine-type serotypes was >95% (3.8–
0.1/100 000 cases; 97%, p <0.001), representing a 64%
decrease for all serotypes (4.7 to 1.7/100 000, p <0.001)
[41]. In the Gambia, vaccine efficacy against meningitis was
92% (95% CI 44–100) for vaccine-type serotypes, but there
was no significant change when considering all serotypes
(vaccine efficacy 22%, 95% CI )84 to 68) [90]. In a US study
of 1379 pneumococcal meningitis cases including 369 chil-
dren (median age 15 months), the overall decrease between
pre-PCV7 and post-PCV7 was less spectacular (30.1%,
p <0.001) [94]. It was, however, higher for children <2 years
old (64%, p <0.001, for all serotypes; 92.8%, p <0.001 for
PCV7 serotypes; 83.5%, p 0.01 for PCV7-related serotypes),
or when only PCV7 serotypes were considered (all ages
combined, 73.3%, p <0.001) [94]. The authors describe also
a significant increase (60.5%, p <0.001) in non-PCV7 sero-
types, such as 19A, 22F and 35B. This is not reassuring
because only 19A is included in PCV13. In France, a less sig-
nificant decline (18%, p 0.03) was observed in children’s
pneumococcal meningitis rates after the introduction of
PCV7, especially in children <2 years old (33%, 8.03–5.41/
100 000 cases; p 0.0006), with a non-significant increase in
older children (0.48–0.56/100 000 cases; p 0.3) [63,95]. It is
still unclear if this reflects a natural fluctuation in disease
incidence or, for example, a serotype replacement.
Mucosal diseases
In the pre-licensure trial, PCV7 had 7% (95% CI 4.1–9.7)
efficacy in preventing acute otitis media with an increased
efficacy in children with recurrent episodes (9.3–22.8%)
[36]. Furthermore, the incidence of ventilatory tube place-
ment decreased by >20% (95% CI 1.5–35.2). In a Cochrane
review the relative reduction of acute otitis media was
between 6% (95% CI )4 to 16) and 7% (95% CI 4.1–9.7)
in PCV7-vaccinated children <12 years, and the relative
reduction of recurrent acute otitis media was between 9%
(95% CI 3–15) and 56% (95% CI )2 to 81)[96]. In another
study, PCV7 vaccination decreased pneumococcal acute oti-
tis media by 48% (p <0.001), with a 38% (p <0.001)
decrease in otorrhoea visits as a collateral benefit [97].
Although these reductions might appear marginal from an
individual point of view, they may possibly have an impor-
tant economic impact on public health because acute otitis
media had an estimated total cost of US$440 million in
2004, all ages combined [96–98].
Pneumococcal carriage
The ecological niche of S. pneumoniae is the nasopharynx
[99]. Although not the main objective of pneumococcal vac-
cines, their efficacy in decreasing carriage has been disap-
pointing. Some researchers found a decrease of the vaccine
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serotypes in colonization (p <0.05), but non-vaccine
serotypes have been increasing and co-colonization with
other microorganisms has remained stable [100–102]. How-
ever, it seems that the number of doses received has an
impact on carriage: the more doses, the lower the coloniza-
tion rate [100,103]. Similarly, the impact on carriage appears
to be serotype-dependent [104]. The less expected effect
was the impact of the conjugate vaccination of children on
adult carriage (83.9% decrease in PCV7-type pneumococcal
carriage, p <0.001), which might explain the decrease in IPD
in adults [52]. It is possible that pneumococcal vaccination
selected in the nasopharynx serotypes that have less disease
potential.
The impact of PCV13 on carriage remains unclear, but
within 1 year of PCV13 implementation, Cohen et al. showed
a significant decrease of serotypes 19A (p <0.001), 7F
(p 0.01) and 6C (p 0.003) carriage among PCV13-vaccinated
children without the emergence of new serotypes [65]. This
led to the rapid replacement of PCV7 by PCV13 [105–107].
Nevertheless, some studies reported that antibody levels
against certain serotypes (6B and 23F) did not achieve the
protective threshold after a primary series of PCV13 vaccina-
tion [108].
Side effects and safety profile
The safety profile of pneumococcal vaccines more than a
decade after large-scale implementation is reassuring [19,36].
Following pneumococcal vaccination, local reactions are mild
in severity and usually last no more than 1 or 2 days. Sys-
temic reactions, such as fever, irritability, decreased appetite,
increased or decreased sleep, are also frequent (Table 4). In
terms of serious side effects of PCV7, both the Vaccine
TABLE 4. Reported side effects following administration of pneumococcal conjugate vaccines (PCV7 and PCV13)a
Adverse event
Frequency (%)
PCV13 PCV7
Local Pain/tenderness Any 24.3–72.7
Very common
14.7–84.4
Significant (interfering with movement) 1.8–15.4
Common
3.5–12.2
Erythema Any 16.2–54.4
Very common
10.0–65.5
Moderate (>2.5 cm) 1.7–37.8
Common
0–14.0
Severe (>7 cm) 0
Uncommon
0
Induration/swelling Any 16.4–44.0
Very common
9.8–50.7
Moderate (>2.5 cm) 0–25.0
Very common
0.1–14.3
Severe (>7 cm) 0
Uncommon
0
Systemic Fever <39C 16.7–63.7
Very common
15.1–60.6
>39C but <40C 2.0–9.6
Common
0–12.5
>40C 0–1.7 0–1.3
Decreased appetite 22.7–70.0
Very common
22.9–73.6
Irritability 51.4–92.0
Very common
53.8–93.1
Drowsiness/increased sleep 34.6–79.5
Very common
41.0–78.5
Restless/decreased sleep 18.6–60.4
Very common
17.7–64.2
Crying Uncommon
Immune system disorders Hypersensitivity reaction (including face oedema, dyspnoea, bronchospasm) Rare
Anaphylactic/anaphylactoid reaction including shock Rare
Angio-oedema Rare
Nervous system disorders Convulsions (including febrile convulsions) Rare
Hypotonic-hyporesponsive episode Rare
Gastrointestinal disorders Vomiting Uncommon
Diarrhoea Uncommon
Blood and lymphatic system disorders Lymphadenopathy (localised to the region of the injection site) Very rare
aAdapted from references [17,21,108,110,116].
PCV7, seven-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
Frequencies as defined by the European Medicines Agency: very common: >1/10 vaccine injections; common: >1/100 to <1/10 vaccine injections; uncommon: >1/1000 to <1/
100 vaccine injections; rare: >1/10 000 to <1/1000 vaccine injections; very rare: £1/10 000 vaccine injections.
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Adverse Event Reporting System and the European Medi-
cines Agency report frequencies similar to other vaccines
[17,109]. These include anaphylactic and anaphylactoid reac-
tions, serum sickness and thrombocytopenia. Post-licensure
studies of PCV13 do not report an increased risk of serious
adverse events compared with PCV7; nevertheless, surveil-
lance is ongoing [19–21,108,110]. The concurrent administra-
tion of other routine childhood vaccinations does not
increase the rate of side effects, nor does it reduce the elic-
ited immune response [17].
Challenges and future vaccines
The major challenges remaining with pneumococcal vaccina-
tion are PCV-serotype specificity, as well as its high manufac-
turing complexity and cost. As the regional distribution of
predominant serotypes shifts, the coverage of currently used
PCV may not be optimal worldwide. New strategies to
improve vaccines are under investigation and development
[111], such as protein-based, serotype-independent, subunit
vaccines, and whole-cell vaccines.
Protein-based, serotype-independent vaccine targets pro-
teins that are conserved in different (or most) pneumococcal
serotypes. Candidate proteins include surface-expressed vir-
ulence factors to maximize the immune response. This
approach would have the advantage of preventing the selec-
tion pressure and the emergence of new serotypes. The first
protein studied was the pneumococcal surface protein A
(PspA; currently in a phase I trial), but there are many other
candidates, such as pneumolysin, pneumococcal histidine
triad proteins, or pneumococcal surface adhesion A (PsaA).
In the future, it is possible that reverse vaccinology may
identify new proteins that are surface expressed, or that
complete bacterial genome sequencing will pinpoint antigens
conserved among clinical isolates [111].
Killed whole-cell vaccine allows a large number of antigens
to be present simultaneously. The possible advantages of this
approach are low production costs, serotype-independent
mechanisms of protection and, possibly, a variety of adminis-
tration routes (intranasal, oral, sublingual, transcutaneous,
subcutaneous and intramuscular). Phase I trials should have
started at the end of 2011 with a vaccine administered par-
enterally [111].
Although some of these vaccines are currently in phase I
clinical trials, most are still in preclinical studies. In addition,
the production of vaccines tailored according to regions,
including only the locally prevalent serotypes, could become
an option if production costs are controlled [112]. Novel
technologies could make PCV more affordable worldwide
and so expand coverage by reducing costs, especially in
countries with limited resources [111]. The GAVI Alliance
(formerly the ‘Global Alliance for Vaccines and Immunisa-
tion’), has been instrumental in promoting the private–pub-
lic partnership of all the main players in immunization into
one decision-making body. Through this partnership, negoti-
ations between industry and the creation of an Advanced
Market Commitment for pneumococcal vaccine has already
led to lower vaccine prices in several developing countries
[113].
In conclusion, more than a decade after the implementa-
tion of PCV in children, the impact on IPD especially is tre-
mendous. In countries where it was implemented and
coverage is high, reduction of IPD is significant and has
impacts indirectly, through herd immunity, on non-vaccinated
older and younger individuals. Pneumococcal disease remains
an important global health issue, particularly in young chil-
dren, and universal, affordable, available vaccination must be
a priority.
Acknowledgements
We thank Rosemary Sudan for editorial assistance.
Conflicts of interest
Nothing to declare.
References
1. Organization WH. New and under-utilized vaccines implementation
(nuvi): Streptococcus pneumoniae (pneumococcus). 2011. http://www.
who.int/nuvi/pneumococcus/en/ (last accessed on June 29, 2012)
2. Zangeneh TT, Baracco G, Al-Tawfiq JA. Impact of conjugate pneu-
mococcal vaccines on the changing epidemiology of pneumococcal
infections. Expert Rev Vaccines 2011; 10: 345–353.
3. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV,
Parks DJ. The epidemiology of invasive pneumococcal disease in
Alaska, 1986–1990 – ethnic differences and opportunities for pre-
vention. J Infect Dis 1994; 170: 368–376.
4. Harrison LH, Dwyer DM, Billmann L, Kolczak MS, Schuchat A. Inva-
sive pneumococcal infection in Baltimore, MD: implications for
immunization policy. Arch Intern Med 2000; 160: 89–94.
5. Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive
pneumococcal disease in central Australia. Med J Aust 1995; 162:
182–186.
6. Musher DM, Ceasar H, Kojic EM et al. Administration of protein-
conjugate pneumococcal vaccine to patients who have invasive dis-
ease after splenectomy despite their having received 23-valent pneu-
mococcal polysaccharide vaccine. J Infect Dis 2005; 191: 1063–1067.
7. Henrichsen J. Six newly recognized types of Streptococcus pneumo-
niae. J Clin Microbiol 1995; 33: 2759–2762.
32 Clinical Microbiology and Infection, Volume 18 Supplement 5, October 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 25–36
8. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm
MH. Discovery of a new capsular serotype (6c) within serogroup 6 of
Streptococcus pneumoniae. J Clin Microbiol 2007; 45: 1225–1233.
9. Jourdain S, Smeesters PR, Denis O et al. Differences in nasopharyn-
geal bacterial carriage in preschool children from different socio-
economic origins. Clin Microbiol Infect 2010; 17: 907–914.
10. Gray BM, Dillon HC Jr. Epidemiological studies of Streptococcus pneu-
moniae in infants: antibody to types 3, 6, 14, and 23 in the first two
years of life. J Infect Dis 1988; 158: 948–955.
11. Gray BM, Dillon HC Jr. Clinical and epidemiologic studies of pneu-
mococcal infection in children. Pediatr Infect Dis J 1986; 5: 201–207.
12. Musher DM. How contagious are common respiratory tract infec-
tions? N Engl J Med 2003; 348: 1256–1266.
13. Ma¨kela¨ PH, Butler JC. History of pneumococcal immunization. In:
Siber GR, Klugman KP, Ma¨kela¨ PH, eds, Pneumococcal vaccines: the
impact of conjugate vaccine. Washington, DC: ASM Press, 2008; 19–
29.
14. Macleod CM, Hodges RG, Heidelberger M, Bernhard WG. Preven-
tion of pneumococcal pneumonia by immunization with specific cap-
sular polysaccharides. J Exp Med 1945; 82: 445–465.
15. Williams C, Masterton R. Pneumococcal immunisation in the 21st
century. J Infect 2008; 56: 13–19.
16. Centers for Disease Control and Prevention (CDC), Advisory Com-
mittee on Immunization Practices. Updated recommendations for
prevention of invasive pneumococcal disease among adults using the
23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR
Morb Mortal Wkly Rep 2010; 59: 1102–1106.
17. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among
infants and children – use of 13-valent pneumococcal conjugate vac-
cine and 23-valent pneumococcal polysaccharide vaccine – recom-
mendations of the advisory committee on immunization practices
(ACIP). MMWR Recomm Rep 2010; 59: 1–18.
18. Fedson DS, Nicolas-Spony L, Klemets P et al. Pneumococcal polysac-
charide vaccination for adults: new perspectives for Europe. Expert
Rev Vaccines 2011; 10: 1143–1167.
19. Paradiso PR. Advances in pneumococcal disease prevention:
13-valent pneumococcal conjugate vaccine for infants and children.
Clin Infect Dis 2011; 52: 1241–1247.
20. Sucher AJ, Chahine EB, Nelson M, Sucher BJ. Prevnar 13, the new
13-valent pneumococcal conjugate vaccine. Ann Pharmacother 2011;
45: 1516–1524.
21. Yeh SH, Gurtman A, Hurley DC et al. Immunogenicity and safety of
13-valent pneumococcal conjugate vaccine in infants and toddlers.
Pediatrics 2010; 126: e493–e505.
22. Vesikari T, Wysocki J, Chevallier B et al. Immunogenicity of the 10-
valent pneumococcal non-typeable Haemophilus influenzae protein d
conjugate vaccine (phid-cv) compared to the licensed 7VCRM vac-
cine. Pediatr Infect Dis J 2009; 28: S66–S76.
23. Chevallier B, Vesikari T, Brzostek J et al. Safety and reactogenicity of
the 10-valent pneumococcal non-typeable Haemophilus influenzae
protein d conjugate vaccine (phid-cv) when coadministered with
routine childhood vaccines. Pediatr Infect Dis J 2009; 28: S109–S118.
24. Knuf M, Szenborn L, Moro M et al. Immunogenicity of routinely used
childhood vaccines when coadministered with the 10-valent pneu-
mococcal non-typeable Haemophilus influenzae protein d conjugate
vaccine (phid-cv). Pediatr Infect Dis J 2009; 28: S97–S108.
25. Bermal N, Szenborn L, Chrobot A et al. The 10-valent pneumococ-
cal non-typeable Haemophilus influenzae protein d conjugate vaccine
(phid-cv) coadministered with dtpw-hbv/hib and poliovirus vaccines:
assessment of immunogenicity. Pediatr Infect Dis J 2009; 28: S89–S96.
26. Van den Bergh MR, Spijkerman J, Francois N et al. Immunogenicity,
safety, and reactogenicity of the 10-valent pneumococcal nontype-
able Haemophilus influenzae protein d conjugate vaccine and DTPa-
IPV-Hib when coadministered as a 3-dose primary vaccination
schedule in the Netherlands: a randomized controlled trial. Pediatr
Infect Dis J 2011; 30: e170–e178.
27. Wysocki J, Tejedor JC, Grunert D et al. Immunogenicity of the 10-
valent pneumococcal non-typeable Haemophilus influenzae protein d
conjugate vaccine (phid-cv) when coadministered with different Nei-
sseria meningitidis serogroup c conjugate vaccines. Pediatr Infect Dis J
2009; 28: S77–S88.
28. Knuf M, Pankow-Culot H, Grunert D et al. Induction of immunologic
memory following primary vaccination with the 10-valent pneumo-
coccal nontypeable Haemophilus influenzae protein d conjugate vac-
cine in infants. Pediatr Infect Dis J 2012; 31: e31–e36.
29. World Health Organization. Pneumococcal conjugate vaccine for
childhood immunization – who position paper. Wkly Epidemiol Rec
2007; 82: 93–104.
30. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immuno-
genicity, reactogenicity and safety of a 7-valent pneumococcal conju-
gate vaccine (PCV7) concurrently administered with a DTPa-HBV-
IPV/Hib combination vaccine in healthy infants. Vaccine 2006; 24:
4727–4736.
31. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, effi-
cacy, safety and effectiveness of pneumococcal conjugate vaccines
(1998–2006). Vaccine 2007; 25: 2194–2212.
32. Lin PL, Michaels MG, Green M et al. Safety and immunogenicity of the
American Academy of Pediatrics – recommended sequential pneumo-
coccal conjugate and polysaccharide vaccine schedule in pediatric solid
organ transplant recipients. Pediatrics 2005; 116: 160–167.
33. Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evalua-
tion and licensing of new pneumococcal vaccines, 7–8 July 2008,
Ottawa, Canada. Vaccine 2009; 27: 3681–3688.
34. Dinleyici EC, Yargic ZA. Current knowledge regarding the investiga-
tional 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines
2009; 8: 977–986.
35. Vanderkooi OG, Scheifele DW, Girgenti D et al. Safety and immu-
nogenicity of a 13-valent pneumococcal conjugate vaccine in healthy
infants and toddlers given with routine pediatric vaccinations in Can-
ada. Pediatr Infect Dis J 2012; 31: 72–77.
36. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunoge-
nicity of heptavalent pneumococcal conjugate vaccine in children.
Northern California Kaiser Permanente Vaccine Study Center
Group. Pediatr Infect Dis J 2000; 19: 187–195.
37. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumo-
coccal disease after the introduction of protein-polysaccharide con-
jugate vaccine. N Engl J Med 2003; 348: 1737–1746.
38. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control
of pneumococcal disease in the UK – the impact of vaccination. J
Med Microbiol 2011; 60: 1–8.
39. Black S, France EK, Isaacman D et al. Surveillance for invasive pneu-
mococcal disease during 2000–2005 in a population of children who
received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J
2007; 26: 771–777.
40. Grijalva CG, Pelton SI. A second-generation pneumococcal conju-
gate vaccine for prevention of pneumococcal diseases in children.
Curr Opin Pediatr 2011; 23: 98–104.
41. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in inva-
sive pneumococcal disease in the era of conjugate vaccine. J Infect
Dis 2010; 201: 32–41.
42. Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of
invasive pneumococcal disease in Australian children after introduc-
tion of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011;
194: 116–120.
43. Ruckinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt
F, Siedler A. Reduction in the incidence of invasive pneumococcal
disease after general vaccination with 7-valent pneumococcal conju-
gate vaccine in Germany. Vaccine 2009; 27: 4136–4141.
CMI Pittet and Posfay-Barbe Pneumococcal vaccines for children 33
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 25–36
44. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center
attendees reduces carriage of Streptococcus pneumoniae among their
younger siblings. Pediatr Infect Dis J 2003; 22: 524–532.
45. Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal dis-
ease among infants before and after introduction of pneumococcal
conjugate vaccine. JAMA 2006; 295: 1668–1674.
46. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP.
Impact of pneumococcal conjugate vaccination of infants on pneu-
monia and influenza hospitalization and mortality in all age groups in
the United States. MBio 2011; 2: e00309–e00310.
47. Talbot TR, Poehling KA, Hartert TV et al. Reduction in high rates of
antibiotic-nonsusceptible invasive pneumococcal disease in Tennes-
see after introduction of the pneumococcal conjugate vaccine. Clin
Infect Dis 2004; 39: 641–648.
48. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of
the pneumococcal conjugate vaccine on drug-resistant Streptococcus
pneumoniae. N Engl J Med 2006; 354: 1455–1463.
49. Black S, Shinefield H, Baxter R et al. Postlicensure surveillance for
pneumococcal invasive disease after use of heptavalent pneumococ-
cal conjugate vaccine in northern California Kaiser Permanente. Pedi-
atr Infect Dis J 2004; 23: 485–489.
50. Stephens DS, Zughaier SM, Whitney CG et al. Incidence of macro-
lide resistance in Streptococcus pneumoniae after introduction of the
pneumococcal conjugate vaccine: population-based assessment. Lan-
cet 2005; 365: 855–863.
51. Flannery B, Heffernan RT, Harrison LH et al. Changes in invasive
pneumococcal disease among HIV-infected adults living in the era of
childhood pneumococcal immunization. Ann Intern Med 2006; 144:
1–9.
52. Hammitt LL, Bruden DL, Butler JC et al. Indirect effect of conjugate
vaccine on adult carriage of Streptococcus pneumoniae: an explanation
of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:
1487–1494.
53. Haber M, Barskey A, Baughman W et al. Herd immunity and pneu-
mococcal conjugate vaccine: a quantitative model. Vaccine 2007; 25:
5390–5398.
54. O’Brien KL, Dagan R. The potential indirect effect of conjugate
pneumococcal vaccines. Vaccine 2003; 21: 1815–1825.
55. Ho PL, Chiu SS, Chan MY, Ang I, Chow KH, Lau YL. Changes in
nasopharyngeal carriage and serotype distribution of antibiotic-resis-
tant Streptococcus pneumoniae before and after the introduction of 7-
valent pneumococcal conjugate vaccine in Hong Kong. Diagn Micro-
biol Infect Dis 2011; 71: 327–334.
56. Henriques-Normark B, Blomberg C, Dagerhamn J, Battig P, Nor-
mark S. The rise and fall of bacterial clones: Streptococcus pneumo-
niae. Nat Rev Microbiol 2008; 6: 827–837.
57. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumo-
coccal disease and serotype distribution among Streptococcus pneu-
moniae isolates in young children in Europe: impact of the 7-valent
pneumococcal conjugate vaccine and considerations for future con-
jugate vaccines. Int J Infect Dis 2010; 14: e197–e209.
58. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement
and multiple resistance in Streptococcus pneumoniae after the intro-
duction of the conjugate pneumococcal vaccine. Microb Drug Resist
2008; 14: 101–107.
59. Hsu KK, Shea KM, Stevenson AE, Pelton SI. Changing serotypes
causing childhood invasive pneumococcal disease: Massachusetts,
2001–2007. Pediatr Infect Dis J 2010; 29: 289–293.
60. Wongsawat J, Chokephaibulkit K. Implication of pneumococcal con-
jugate vaccines to public health: Thailand perspective. J Med Assoc
Thai 2010; 93 (Suppl 5): S53–S60.
61. Cornick JE, Everett DB, Broughton C et al. Invasive Streptococcus
pneumoniae in children, Malawi, 2004–2006. Emerg Infect Dis 2011;
17: 1107–1109.
62. Office Fe´de´ral de la Sante´ Publique (OFSP). [Maladies a` pneumoco-
ques 2009]. Bulletin de l’OFSP 2010; 47: 7.
63. Bingen E, Levy C, Varon E et al. Pneumococcal meningitis in the era
of pneumococcal conjugate vaccine implementation. Eur J Clin Micro-
biol Infect Dis 2008; 27: 191–199.
64. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient
antibiotic use in Europe and association with resistance: a cross-
national database study. Lancet 2005; 365: 579–587.
65. Cohen R, Levy C, Bingen E et al. Impact of 13-valent pneumococcal
conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children
with acute otitis media (AOM). In: Abstracts book of the 51st Inter-
science Congress on Antimicrobial Agents and Chemotherapy, Chicago,
IL, September 17–20, 2011; abstr. no. G3-1709.
66. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines
on antibiotic resistance. Lancet Infect Dis 2008; 8: 785–795.
67. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by
serotype 19a: review of the literature and implications for future
vaccine development. Vaccine 2010; 28: 4249–4259.
68. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvac-
cine genetic structure of Streptococcus pneumoniae serotype 19A from
children in the United States. J Infect Dis 2005; 192: 1988–1995.
69. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of
emergent Streptococcus pneumoniae serotype 19A in the United
States, 2005. J Infect Dis 2008; 197: 1016–1027.
70. Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Ap-
pelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae
in eight European countries from 2001 to 2003. Antimicrob Agents
Chemother 2005; 49: 2903–2913.
71. Pichichero ME, Casey JR. Emergence of a multiresistant serotype
19A pneumococcal strain not included in the 7-valent conjugate vac-
cine as an otopathogen in children. JAMA 2007; 298: 1772–1778.
72. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resis-
tance among nonvaccine serotypes of Streptococcus pneumoniae in
the pediatric population after the introduction of 7-valent pneumo-
coccal vaccine in the United States. Pediatr Infect Dis J 2007; 26:
123–128.
73. Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus
pneumoniae causing multidrug-resistant acute otitis media in children.
Emerg Infect Dis 2009; 15: 547–551.
74. Gessner BD, Mueller JE, Yaro S. African meningitis belt pneumococ-
cal disease epidemiology indicates a need for an effective serotype 1
containing vaccine, including for older children and adults. BMC Infect
Dis 2010; 10: 22.
75. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO.
Impact of the pneumococcal conjugate vaccine on pneumococcal
parapneumonic empyema. Pediatr Infect Dis J 2006; 25: 250–254.
76. Ho PL, Chiu SS, Ang I, Lau YL. Serotypes and antimicrobial suscepti-
bilities of invasive Streptococcus pneumoniae before and after intro-
duction of 7-valent pneumococcal conjugate vaccine, Hong Kong,
1995–2009. Vaccine 2011; 29: 3270–3275.
77. CDC CfDCaP. Invasive pneumococcal disease and 13-valent pneu-
mococcal conjugate vaccine (PCV13) coverage among children aged
£59 months – selected U.S. Regions, 2010–2011. MMWR Morb Mor-
tal Wkly Rep 2011; 60: 4.
78. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effective-
ness of the new serotypes in the 13-valent pneumococcal conjugate
vaccine. Vaccine 2011; 29: 9127–9131.
79. Herrero M, Alcalde M, Gomez B et al. Invasive bacterial infec-
tions in a paediatric emergency department in the era of the hep-
tavalent pneumococcal conjugate vaccine. Eur J Emerg Med 2012;
19: 89–94.
80. Jacobs MR, Bajaksouzian S, Good CE, Windau AR, Gonzalez B. Evo-
lution of Streptococcus pneumoniae serotypes following introduction
of the 13-valent conjugate pneumococcal vaccine. In: Abstracts book
34 Clinical Microbiology and Infection, Volume 18 Supplement 5, October 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 25–36
of the 51st Interscience Congress on Antimicrobial Agents and Chemother-
apy, Chicago, IL, September 17–20, 2011; abstr. no.G3-773.
81. Van der Linden M, Ru¨ckinger S, Imo¨hl M. First effects of immuniza-
tion with higher valent pneumococcal conjugate vaccines in German
children on numbers of reported invasive pneumococcal disease
(IPD) cases. In: Abstracts book of the 51st Interscience Congress on Anti-
microbial Agents and Chemotherapy, Chicago, IL, September 17–20,
2011; abstr. no G3-775.
82. Singleton RWJ, Klejka JA, Bulkow LR et al. Impact of the 13-valent
pneumococcal conjugate vaccine on invasive pneumococcal disease
in Alaska Native children: results of a clinical trial. In: Abstracts book
of the 29th Annual Meeting of the European Society of Paediatric Infec-
tious Diseases. The Hague, Netherlands, June 7–11, 2011; abstr. no.
691.
83. Moore ML-GR, Farlex M, Thomas A et al. Conjugate vaccine on
invasive pneumococcal disease among children <2 years old, U.S.
2010. In: Abstracts book of the 51st Interscience Congress on Anti-
microbial Agents and Chemotherapy, Chicago, IL, September 17–20,
2011; abstr. no G1-538.
84. Herz AM, Greenhow TL, Alcantara J et al. Changing epidemiology of
outpatient bacteremia in 3- to 36-month-old children after the intro-
duction of the heptavalent-conjugated pneumococcal vaccine. Pediatr
Infect Dis J 2006; 25: 293–300.
85. Benito-Fernandez J, Raso SM, Pocheville-Gurutzeta I, SanchezEtxaniz
J, Azcunaga-Santibanez B, Capape-Zache S. Pneumococcal bactere-
mia among infants with fever without known source before and
after introduction of pneumococcal conjugate vaccine in the Basque
country of Spain. Pediatr Infect Dis J 2007; 26: 667–671.
86. Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact
of infant pneumococcal vaccination on invasive pneumococcal dis-
eases in France, 2001–2006. Euro Surveill 2008; 13: 1–6.
87. Picazo J, Ruiz-Contreras J, Hernandez B et al. Clonal and clinical
profile of Streptococcus pneumoniae serotype 19A causing pediatric
invasive infections: a 2-year (2007–2009) laboratory-based surveil-
lance in Madrid. Vaccine 2011; 29: 1770–1776.
88. Resti M, Moriondo M, Cortimiglia M et al. Community-acquired bac-
teremic pneumococcal pneumonia in children: diagnosis and serotyp-
ing by real-time polymerase chain reaction using blood samples. Clin
Infect Dis 2010; 51: 1042–1049.
89. Hansen J, Black S, Shinefield H et al. Effectiveness of heptavalent
pneumococcal conjugate vaccine in children younger than 5 years of
age for prevention of pneumonia: updated analysis using World
Health Organization standardized interpretation of chest radio-
graphs. Pediatr Infect Dis J 2006; 25: 779–781.
90. Cutts FT, Zaman SM, Enwere G et al. Efficacy of nine-valent pneu-
mococcal conjugate vaccine against pneumonia and invasive pneumo-
coccal disease in The Gambia: randomised, double-blind, placebo-
controlled trial. Lancet 2005; 365: 1139–1146.
91. Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing incidence of
empyema complicating childhood community-acquired pneumonia in
the United States. Clin Infect Dis 2010; 50: 805–813.
92. Strachan RE, Cornelius A, Gilbert GL et al. Bacterial causes of empy-
ema in children, Australia, 2007–2009. Emerg Infect Dis 2011; 17:
1839–1845.
93. Spencer DA, Close AJ, Simmister C et al. Impact of the 13-valent
pneumococcal vaccine on the incidence of paediatric empyema in
the north of England. In: Abstracts book of the 29th Annual Meeting of
the European Society of Paediatric Infectious Diseases. The Hague,
Netherlands, June 7–11, 2011; abstr. no 637
94. Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conju-
gate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:
244–256.
95. Levy C, Varon E, Bingen E, Lecuyer A, Boucherat M, Cohen R.
Pneumococcal meningitis in French children before and after the
introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J
2011; 30: 168–170.
96. Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG,
Sanders EA. Pneumococcal conjugate vaccines for preventing otitis
media. Cochrane Database Syst Rev 2009: CD001480.
97. Stamboulidis K, Chatzaki D, Poulakou G et al. The impact of the
heptavalent pneumococcal conjugate vaccine on the epidemiology of
acute otitis media complicated by otorrhea. Pediatr Infect Dis J 2011;
30: 551–555.
98. Huang SS, Johnson KM, Ray GT et al. Healthcare utilization and cost
of pneumococcal disease in the United States. Vaccine 2011; 29:
3398–3412.
99. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk
factors, and strategies for prevention. Semin Respir Crit Care Med
2009; 30: 189–209.
100. Kim KH, Hong JY, Lee H et al. Nasopharyngeal pneumococcal
carriage of children attending day care centers in Korea: comparison
between children immunized with 7-valent pneumococcal conjugate
vaccine and non-immunized. J Korean Med Sci 2011; 26: 184–190.
101. Brugger SD, Frey P, Aebi S, Hinds J, Muhlemann K. Multiple coloni-
zation with S. pneumoniae before and after introduction of the
seven-valent conjugated pneumococcal polysaccharide vaccine. PLoS
One 2010; 5: e11638.
102. Kuo CY, Hwang KP, Hsieh YC et al. Nasopharyngeal carriage of
Streptococcus pneumoniae in Taiwan before and after the introduction
of a conjugate vaccine. Vaccine 2011; 29: 5171–5177.
103. Ota MO, Akinsola A, Townend J et al. The immunogenicity and impact
on nasopharyngeal carriage of fewer doses of conjugate pneumococcal
vaccine immunization schedule. Vaccine 2011; 29: 2999–3007.
104. Simell B, Nurkka A, Lahdenkari M et al. Association of serotype-spe-
cific antibody concentrations and functional antibody titers with sub-
sequent pneumococcal carriage in toddlers immunized with 9-valent
pneumococcal conjugate vaccine. Clin Vaccine Immunol 2012; 19: 96–
99.
105. Grimprel E, Laudat F, Patterson S et al. Immunogenicity and safety
of a 13-valent pneumococcal conjugate vaccine (PCV13) when given
as a toddler dose to children immunized with PCV7 as infants. Vac-
cine 2011; 29: 9675–9683.
106. Boccalini S, Azzari C, Resti M et al. Economic and clinical evaluation
of a catch-up dose of 13-valent pneumococcal conjugate vaccine in
children already immunized with three doses of the 7-valent vaccine
in Italy. Vaccine 2011; 29: 9521–9528.
107. Frenck R Jr, Thompson A, Yeh SH et al. Immunogenicity and safety
of 13-valent pneumococcal conjugate vaccine in children previously
immunized with 7-valent pneumococcal conjugate vaccine. Pediatr
Infect Dis J 2011; 30: 1086–1091.
108. Esposito S, Tansey S, Thompson A et al. Safety and immunogenicity
of a 13-valent pneumococcal conjugate vaccine compared to those
of a 7-valent pneumococcal conjugate vaccine given as a three-dose
series with routine vaccines in healthy infants and toddlers. Clin Vac-
cine Immunol 2010; 17: 1017–1026.
109. Wise RP, Iskander J, Pratt RD et al. Postlicensure safety surveillance
for 7-valent pneumococcal conjugate vaccine. JAMA 2004; 292: 1702–
1710.
110. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. Safety and
immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pedi-
atrics 2010; 125: 866–875.
111. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr
Opin Immunol 2011; 23: 407–413.
112. Webster J, Theodoratou E, Nair H et al. An evaluation of emerging
vaccines for childhood pneumococcal pneumonia. BMC Public Health
2011; 11 (Suppl 3): S26.
113. Hargreaves JR, Greenwood B, Clift C et al. Making new vaccines
affordable: a comparison of financing processes used to develop and
CMI Pittet and Posfay-Barbe Pneumococcal vaccines for children 35
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 25–36
deploy new meningococcal and pneumococcal conjugate vaccines.
Lancet 2011; 378: 1885–1893.
114. World Health Organization. WHO vaccine-preventable diseases: moni-
toring system 2011 global summary. 2011. Available at: http://apps.
who.int/immunization_monitoring/en/globalsummary/DiseaseSelect.
cfm?U=years (last accessed on June 29, 2012).
115. World Health Organization – United Nations Children’s Fund.
WHO-UNICEF estimates of PCV3 coverage. 2011. Available at: http://apps.
who.int/immunization_monitoring/en/globalsummary/timeseries/tswu
coveragepcv3.htm (last accessed June 29, 2012)
116. European Medicines Agency. Prevenar 13: European Public Assessment
Report (EPAR) – product information Annexe I: summary of product char-
acteristics. 2011; 1–12. Available at: http://www.ema.europa.eu/docs/
en_GB/document_library/EPAR_-_Product_Information/human/
001104/WC500057247.pdf (last accessed June 29, 2012).
36 Clinical Microbiology and Infection, Volume 18 Supplement 5, October 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 5), 25–36
